Bruker Corporation

BRKR Healthcare Medical Devices

Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024.

Revenue
+1.57%
EPS
−75.4%
Free cash flow
+278.7%
Total debt
−14.7%

Quarter to September 2026, against a year earlier

61.20 3.14 +5.41%
Market cap
$8.9B
P/E
0.0×
Fwd P/E
−412×
Dividend yield
0.33%
F-score
4/9
Altman Z
2.43
Beneish M
−2.56
Dividend safety
34/100

Bruker Corporation 10-Q filed Aug 5, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:24 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 7, 2026: 26 added · 13 removed · 31 modified

  1. Modified

    The following discussion of our financial condition and results of operations should be read in conjunction with our interim unaudited condensed consolidated financial statements and the notes to those statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q, and in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2025 (“2025 Form 10-K”). The dollar amounts listed in the tables presented in Management’s Discussion and Analysis of Financial Condition and Results of Operations are in millions of U.S. Dollars.